Kangmei Pharmaceutical released its 2026 interim report. Total operating revenue was 2.29 billion yuan, and net profit attributable to the parent company was 36.0348 million yuan, an increase of 19.1334 million yuan compared with the same period last year, marking five consecutive years of growth and a year-on-year rise of 113.21%. Net cash inflow from operating activities was 36.0528 million yuan, an increase of 118 million yuan over the same period last year, achieving growth for two consecutive years. The company's asset-liability ratio was 43.66%, down 1.41 percentage points from the previous quarter and down 3.37 percentage points from the same period last year. Gross margin was 21.30%, up 2.46 percentage points year on year, rising for two consecutive years. Return on equity was 0.49%, up 0.26 percentage points from a year earlier. Diluted earnings per share rose 200.00% year on year. Total asset turnover was 0.17 times, and inventory turnover was 0.79 times. The number of shareholders was 285,900, and the top ten shareholders held 4.646 billion shares, accounting for 33.59% of total share capital.
Kangmei Pharmaceutical Co LtdNet profit up 113.21% and operating cash flow improved, indicating strong earnings performance.
